Curasan AG, Pro-Tec Medizinische Produkte GmbH deal

CUR acquired Pro-Tec in a cash deal and obtained all rights to Stypro, Pro-Tec's product to control bleeding and promote wound healing. CUR said it expects Stypro sales of DM 500,000 ($23,000) in 2001...